Lyell Financial Statements From 2010 to 2025
| LYEL Stock | USD 0.61 0.03 5.17% |
Check Lyell Immunopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lyell Immunopharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Lyell financial statements analysis is a perfect complement when working with Lyell Immunopharma Valuation or Volatility modules.
Lyell |
Lyell Immunopharma Company Return On Asset Analysis
Lyell Immunopharma's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Lyell Immunopharma Return On Asset | -0.19 |
Most of Lyell Immunopharma's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lyell Immunopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Lyell Immunopharma has a Return On Asset of -0.1912. This is 97.81% lower than that of the Biotechnology sector and 99.19% lower than that of the Health Care industry. The return on asset for all United States stocks is 36.57% higher than that of the company.
Lyell Immunopharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lyell Immunopharma's current stock value. Our valuation model uses many indicators to compare Lyell Immunopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lyell Immunopharma competition to find correlations between indicators driving Lyell Immunopharma's intrinsic value. More Info.Lyell Immunopharma is rated fifth overall in return on equity category among its peers. It is rated fourth overall in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Lyell Immunopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.About Lyell Immunopharma Financial Statements
Lyell Immunopharma investors utilize fundamental indicators, such as revenue or net income, to predict how Lyell Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Lyell Immunopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 219 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Lyell Immunopharma Correlation against competitors. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.